Yuliia Klitsunova
Zaporizhia Medical Academy, Ukraine
Title: Sitagliptin as combination therapy in the treatment of inadequately controlled type 2 diabetes
Biography
Biography: Yuliia Klitsunova
Abstract
The purpose of this study was to evaluate the effects of sitagliptin 100 mg in the treatment of participants with type 2 diabetes mellitus who have inadequate glycemic control on metformin ≥1500mg/day. Materials and methods: Outpatients aged 52-72 years with type 2 diabetes. Patients were on metformin monotherapy (>=1500 mg/day) for >=8 weeks with a A1C >=7.5% and <=11.0% before treatment with sitagliptin. Glycemic efficacy endpoints were included the changes from baseline in A1C and FPG at week 26 and also Percentage of Participants Achieving a HbA1c of <7%. Other efficacy endpoints that were assessed include changes from baseline at week 26 in body weight, and some safety endpoints such as hepatic safety tests ALT and AST, total and direct bilirubin, renal failure tests - serum creatinite calculated using the CKD-EPI formula, urinary albumin/creatinine ratio. The efficacy and safety were retrospectively evaluated by comparison of laboratory values before and after the administration of sitagliptin and by review of adverse events after treatment.